News Formal

After Roaring In 2020, Biotech Stocks Now Weighed Down By Merger Scrutiny, FDA Approval Delays And Possible Drug Pricing Legislation

  • 📰 Forbes
  • ⏱ Reading Time:
  • 12 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 53%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

After roaring in 2020, biotech stocks are now weighed down by merger scrutiny, FDA approval delays and possible drug pricing legislation

Biotech stocks have been dropping in value since early February, likely depressed by some regulatory and drug pricing concerns, but some analysts think the sector will rebound later this year, partly on the back of M&A deals and new product releases.... [+]

David Nierengarten, a biotech and biopharmaceuticals analyst at Wedbush Securities in Los Angeles, toldthat concerns over stalled new drug approvals by the Food and Drug Administration are likely weighing on the biotech sector.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 394. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

After Roaring In 2020, Biotech Stocks Now Weighed Down By Merger Scrutiny, FDA Approval Delays And Possible Drug Pricing LegislationI have more than 20 yrs experience in writing about financial markets. I am especially interested in history and literature.
ソース: Forbes - 🏆 394. / 53 続きを読む »

After Roaring In 2020, Biotech Stocks Now Weighed Down By Merger Scrutiny, FDA Approval Delays And Possible Drug Pricing LegislationAfter roaring in 2020, biotech stocks are now weighed down by merger scrutiny, FDA approval delays and possible drug pricing legislation
ソース: Forbes - 🏆 394. / 53 続きを読む »